PALISADE BIO INC(NASDAQ:PALI) stock News

PALI Latest News, Press Relases and Analysis

All

Press Releases

7 days ago - By: Chartmill - Mentions: QH LIDR ANGH MCVT ...

The trading volume of these stocks is deviating from the norm in today's session.

10 days ago - By: Chartmill - Mentions: QH LIDR RAYA OCTO ...

Unusual volume stocks in Friday's session

5 days ago - By: Palisade Bio, Inc.

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

12 days ago - By: Benzinga - Mentions: CYCC CYH WST HCTI ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

12 days ago - By: Benzinga - Mentions: IXHL FOXO GOOG RAYA ...

Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

12 days ago - By: Palisade Bio, Inc.

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

14 days ago - By: Palisade Bio, Inc.

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

14 days ago - By: ACCESS Newswire - Mentions: AKTX AMIX CNSP NVNO ...

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

a month ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

2 months ago - By: Palisade Bio, Inc.

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

3 months ago - By: Palisade Bio, Inc.

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

4 months ago - By: Palisade Bio, Inc.

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

5 months ago - By: Palisade Bio, Inc.

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

5 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

5 months ago - By: Palisade Bio, Inc.

Palisade Bio Participates in Virtual Investor “What This Means” Segment

6 months ago - By: Palisade Bio, Inc.

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

6 months ago - By: Palisade Bio, Inc.

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

6 months ago - By: Palisade Bio, Inc.

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

7 months ago - By: Palisade Bio, Inc.

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

7 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

8 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

9 months ago - By: Palisade Bio, Inc.

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

9 months ago - By: Palisade Bio, Inc.

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

9 months ago - By: Palisade Bio, Inc.

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

9 months ago - By: Palisade Bio, Inc.

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

10 months ago - By: Palisade Bio, Inc.

PALISADE BIO INC (PALI) Stock News

PALI Latest News, Press Relases and Analysis

The trading volume of these stocks is deviating from the norm in today's session.

Unusual volume stocks in Friday's session

Palisade Bio Receives Notice of Allowance for Composition of Matter Patent Covering Lead Product Candidate PALI-2108 in China

12 Health Care Stocks Moving In Thursday's Pre-Market Session

Why Alphabet Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket

Palisade Bio Announces Exercise of Previously Issued Warrants for $3.9 Million

Palisade Bio Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference

JTC Team Virtual Investor "What’s Your Story" Summer Spotlight On-Demand Conference Now Live

Palisade Bio Appoints Emil Chuang, MB BS FRACP to its Board of Directors

Palisade Bio Reports Positive Phase 1a Results for PALI-2108, a First-in-Class Terminal Ileum and Colon-Targeted PDE4 B/D Inhibitor for Fibrostenotic Crohn’s Disease and Ulcerative Colitis

Palisade Bio’s AI-Driven Approach to IBD Heterogeneity and Efficacy Selected for Presentation at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit

Palisade Bio Completes Dosing in Phase 1a Portion of Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108

Palisade Bio Announces Two Abstracts Selected to be Showcased as Poster of Distinction and Poster Presentation at Leading GI Forum, Digestive Disease Week (DDW) 2025

Palisade Bio Participates in Virtual Investor “What This Means” Segment

Palisade Bio, Inc. Announces Receipt of Cash Proceeds from Canada’s SR&ED Tax Incentive Program for Reimbursement of Development Costs of PALI-2108 for Treatment of Ulcerative Colitis (UC)

Palisade Bio Presents Positive Preclinical Data of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress

Palisade Bio Completes All Five SAD Cohorts and Advances to MAD Cohorts of Phase 1a/b Study of PALI-2108 for Treatment of Ulcerative Colitis

Palisade Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board

Palisade Bio Announces Closing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Pricing of $5 Million Underwritten Public Offering Priced At-Market Under Nasdaq Rules

Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects

Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn's Disease and Ulcerative Colitis (UC)

Palisade Bio CMO Mitch Jones, MD, PhD, to Present at 8th Annual Antifibrotic Drug Development (AFDD) Summit

Palisade Bio Reports Third Quarter 2024 Financial Results and Outlines Key Accomplishments and Next Steps to Advance Lead Program PALI-2108

Palisade Bio Announces Positive Data from Two Ex Vivo Translational Studies of PALI-2108 for the Treatment of Ulcerative Colitis

Palisade Bio Cleared by Health Canada to Commence Phase 1 Clinical Study for Lead Program, PALI-2108 for the Treatment of Ulcerative Colitis (UC)